prophylactic Valganciclovir — Competitive Intelligence Brief

prophylactic Valganciclovir (prophylactic Valganciclovir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Infectious Disease / Virology.

marketed Nucleoside analog antiviral CMV DNA polymerase Infectious Disease / Virology Small molecule

Target snapshot

prophylactic Valganciclovir (prophylactic Valganciclovir) — Rabin Medical Center. Valganciclovir is a prodrug of ganciclovir that inhibits viral DNA polymerase to prevent cytomegalovirus (CMV) replication in immunocompromised patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
prophylactic Valganciclovir TARGET	prophylactic Valganciclovir	Rabin Medical Center	marketed	Nucleoside analog antiviral	CMV DNA polymerase
Placebo to VGCV	Placebo to VGCV	Merck Sharp & Dohme LLC	phase 3	Nucleoside analog antiviral	CMV DNA polymerase
Valganciclovir CMV Prophylaxis	Valganciclovir CMV Prophylaxis	University of California, San Francisco	phase 3	Nucleoside analog antiviral	CMV DNA polymerase
Prophylaxis with valganciclovir plus mycophenolate	Prophylaxis with valganciclovir plus mycophenolate	University of Bologna	phase 3	Combination antiviral and immunosuppressant	CMV DNA polymerase (valganciclovir); IMPDH type II (mycophenolate)
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Ribavirin (SCH 018908)	Ribavirin (SCH 018908)	Merck Sharp & Dohme LLC	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; GTP depletion

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-09-22 — Lonsurf · RE46284 · US
• 2034-06-17 — Lonsurf · 10457666 · US
• 2034-06-17 — Lonsurf · 9527833 · US
• 2034-09-05 — Lonsurf · 9943537 · US
• 2037-02-03 — Lonsurf · 10456399 · US
• 2037-02-03 — Lonsurf · 10960004 · US

Sponsor landscape (Nucleoside analog antiviral class)

1. Merck Sharp & Dohme LLC · 3 drugs in this class
2. Hoffmann-La Roche · 2 drugs in this class
3. Göteborg University · 2 drugs in this class
4. Estetra · 1 drug in this class
5. Padagis LLC · 1 drug in this class
6. MinaPharm Pharmaceuticals · 1 drug in this class
7. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
8. NYU Langone Health · 1 drug in this class
9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
10. Ain Shams University · 1 drug in this class